Cyclacel Pharmaceuticals, Inc.
20
1
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
35.0%
7 terminated/withdrawn out of 20 trials
53.3%
-33.2% vs industry average
5%
1 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Role: collaborator
Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Role: collaborator
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
Role: lead
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Role: lead
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Role: lead
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Role: lead
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Role: lead
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Role: lead
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Role: lead
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Role: lead
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Role: lead
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Role: lead
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Role: lead
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
Role: lead
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Role: lead
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Role: lead
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Role: lead
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
Role: lead
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Role: collaborator
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Role: lead
All 20 trials loaded